Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KARMA: Ketamine mechanism in remitted depression
NCT04656886Completed
- Sponsor
- King's College London
- Start
- Sep 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
01
Overview
Randomised trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by King's College London. Primary endpoints: Activation of brain areas important for autobiographical emotional memory recall and Activation of brain areas important for reward processing and anhedonia. Started Sep 2014; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04656886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656886.